Immunotherapies to optimize pregnancy outcomes in subfertile women
- 6 May 2022
- journal article
- letter
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 28 (4) , 601-602
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Reply: Immunotherapies to optimize pregnancy outcomes in subfertile womenHuman Reproduction Update, 2022
- The Endometrial Immune Profiling May Positively Affect the Management of Recurrent Pregnancy LossFrontiers in Immunology, 2021
- Lymphocyte immunotherapy in recurrent miscarriage and recurrent implantation failureAmerican Journal of Reproductive Immunology, 2021
- Efficacy of intrauterine administration of autologous peripheral blood mononuclear cells on the pregnancy outcomes in patients with recurrent implantation failure: A systematic review and meta-analysisJournal of Reproductive Immunology, 2020
- The role of immunotherapy in in vitro fertilization and recurrent pregnancy loss: a systematic review and meta-analysisFertility and Sterility, 2018
- Lymphocyte immunotherapy for recurrent miscarriages: Predictors of therapeutic successAmerican Journal of Reproductive Immunology, 2018
- Intrauterine administration of autologous peripheral blood mononuclear cells (PBMCs) activated by HCG improves the implantation and pregnancy rates in patients with repeated implantation failure: a prospective randomized studyAmerican Journal of Reproductive Immunology, 2016
- Intrauterine insemination of cultured peripheral blood mononuclear cells prior to embryo transfer improves clinical outcome for patients with repeated implantation failuresZygote, 2015
- CONTROLLED TRIAL OF TREATMENT OF RECURRENT SPONTANEOUS ABORTION BY IMMUNISATION WITH PATERNAL CELLSThe Lancet, 1985
- PREVENTION OF RECURRENT ABORTION WITH LEUCOCYTE TRANSFUSIONSThe Lancet, 1981